Top

Published in:

01-10-2019 | Prostate Cancer | Comorbidities

Malignancy risk in Korean male patients with ankylosing spondylitis

Authors: Bora Nam, Hyoungyoung Kim, Eun Jin Jang, Soo-Kyung Cho, Yoon-Kyoung Sung, Tae-Hwan Kim

Published in: Rheumatology International | Issue 10/2019

Abstract

The objective of this study is to determine the overall and specific cancer risks in male patients with ankylosing spondylitis (AS). From the claims database of the Health Insurance and Review Assessment, male patients with AS without prior cancer history were selected (n = 21,780). Stratified random samples of claims data were used as a reference general male population group (n = 342,361). Incidence rates of overall and types of cancer were presented as number of events per 10,000 person-years with 95% confidence interval (CI). A standardized incidence ratio (SIR) was used to represent the association between AS and cancer, accounting for person-years at risk. Compared to a general male population group, the overall incidence of cancer was increased in male patients with AS (SIR 1.25, 95% CI 1.15–1.36). For specific malignancy types, the risks of male reproductive system malignancy (SIR 1.97, 95% CI 1.59–2.35) and pancreatic cancer (SIR 1.75, 95% CI 1.12–2.37) were increased. Male patients with AS had increased cancer risk, especially for male reproductive system and pancreatic cancer.

Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379–1390. https://doi.org/10.1016/S0140-6736(07)60635-7 CrossRefPubMed

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to virchow? Lancet 357(9255):539–545. https://doi.org/10.1016/S0140-6736(00)04046-0 CrossRefPubMed

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867. https://doi.org/10.1038/nature01322 CrossRefPubMedPubMedCentral

Munn LL (2017) Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med. https://doi.org/10.1002/wsbm.1370 CrossRefPubMed

Yang Z, Lin F, Qin B, Liang Y, Zhong R (2015) Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42(2):282–291. https://doi.org/10.3899/jrheum.140566 CrossRefPubMed

Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S (2015) Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 17:212. https://doi.org/10.1186/s13075-015-0728-9 CrossRefPubMedPubMedCentral

Onishi A, Sugiyama D, Kumagai S, Morinobu A (2013) Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65(7):1913–1921. https://doi.org/10.1002/art.37969 CrossRefPubMed

Liang Y, Yang Z, Qin B, Zhong R (2014) Primary Sjogren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73(6):1151–1156. https://doi.org/10.1136/annrheumdis-2013-203305 CrossRefPubMed

Feltelius N, Ekbom A, Blomqvist P (2003) Cancer incidence among patients with ankylosing spondylitis in Sweden 1965–95: a population based cohort study. Ann Rheum Dis 62(12):1185–1188CrossRefPubMedPubMedCentral

10.

Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N (2006) Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 65(9):1184–1187. https://doi.org/10.1136/ard.2005.047514 CrossRefPubMedPubMedCentral

11.

Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, Baecklund E, Askling J (2014) Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 66(5):1282–1290. https://doi.org/10.1002/art.38339 CrossRefPubMed

12.

Chang CC, Chang CW, Nguyen PA, Chang TH, Shih YL, Chang WY, Horng JT, Lee OK, Ho JH (2017) Ankylosing spondylitis and the risk of cancer. Oncol Lett 14(2):1315–1322. https://doi.org/10.3892/ol.2017.6368 CrossRefPubMedPubMedCentral

13.

Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32(5):718–728. https://doi.org/10.3346/jkms.2017.32.5.718 CrossRefPubMedPubMedCentral

14.

Kim L, Kim JA, Kim S (2014) A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 36:e2014008. https://doi.org/10.4178/epih/e2014008 CrossRefPubMedPubMedCentral

15.

Jung KW, Won YJ, Kong HJ, Lee ES, Community of Population-Based Regional Cancer R (2018) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 50(2):303–316. https://doi.org/10.4143/crt.2018.143 CrossRefPubMedPubMedCentral

16.

Deng C, Li W, Fei Y, Li Y, Zhang F (2016) Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep 6:32063. https://doi.org/10.1038/srep32063 CrossRefPubMedPubMedCentral

17.

Egiziano G, Bernatsky S, Shah AA (2016) Cancer and autoimmunity: harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol 30(1):53–62. https://doi.org/10.1016/j.berh.2016.03.001 CrossRefPubMedPubMedCentral

18.

Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, Ollier WE, Martin J, Gonzalez-Gay MA (2007) Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum 37(1):31–38. https://doi.org/10.1016/j.semarthrit.2007.01.002 CrossRefPubMed

19.

Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88(5):284–293. https://doi.org/10.1097/MD.0b013e3181b76ab5 CrossRef

20.

Baldini C, Pepe P, Luciano N, Ferro F, Talarico R, Grossi S, Tavoni A, Bombardieri S (2012) A clinical prediction rule for lymphoma development in primary Sjogren’s syndrome. J Rheumatol 39(4):804–808. https://doi.org/10.3899/jrheum.110754 CrossRefPubMed

21.

Alcalay M, Bontoux D, Maire P, Matuchansky C, Alcalay D, Tanzer J (1982) HLA-B27 and colorectal cancer. N Engl J Med 307(7):443–444. https://doi.org/10.1056/NEJM198208123070718 CrossRefPubMed

22.

Au WY, Hawkins BR, Cheng N, Lie AK, Liang R, Kwong YL (2001) Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol 115(2):320–322CrossRefPubMed

23.

Hammer RE, Richardson JA, Simmons WA, White AL, Breban M, Taurog JD (1995) High prevalence of colorectal cancer in HLA-B27 transgenic F344 rats with chronic inflammatory bowel disease. J Investig Med 43(3):262–268PubMed

24.

Endogenous H, Prostate Cancer Collaborative G, Roddam AW, Allen NE, Appleby P, Key TJ (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100(3):170–183. https://doi.org/10.1093/jnci/djm323 CrossRef

25.

Bostwick DG, Cheng L (2012) Precursors of prostate cancer. Histopathology 60(1):4–27. https://doi.org/10.1111/j.1365-2559.2011.04007.x CrossRefPubMed

26.

Bostwick DG, Liu L, Brawer MK, Qian J (2004) High-grade prostatic intraepithelial neoplasia. Rev Urol 6(4):171–179PubMedPubMedCentral

27.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, Group RS (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192–1202. https://doi.org/10.1056/nejmoa0908127 CrossRefPubMed

28.

Straub RH, Struharova S, Scholmerich J, Harle P (2002) No alterations of serum levels of adrenal and gonadal hormones in patients with ankylosing spondylitis. Clin Exp Rheumatol 20(6 Suppl 28):S52–S59PubMed

29.

Shang Z, Wang X, Yan H, Cui B, Wang Q, Wu J, Cui X, Li J, Ou T, Yang K (2018) Intake of non-steroidal anti-inflammatory drugs and the risk of prostate cancer: a meta-analysis. Front Oncol 8:437. https://doi.org/10.3389/fonc.2018.00437 CrossRefPubMedPubMedCentral

30.

Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388(10039):73–85. https://doi.org/10.1016/S0140-6736(16)00141-0 CrossRefPubMed

31.

Rudwaleit M, Baeten D (2006) Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 20(3):451–471. https://doi.org/10.1016/j.berh.2006.03.010 CrossRefPubMed

32.

Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19(4):789–799. https://doi.org/10.1097/MIB.0b013e31828029c0 CrossRefPubMed

33.

Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D, Force USPST (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 146(5):376–389CrossRefPubMed

34.

Flossmann E, Rothwell PM, British Doctors Aspirin T, The UKTIAAT (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369(9573):1603–1613. https://doi.org/10.1016/S0140-6736(07)60747-8 CrossRefPubMed

35.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET, Investigators APCS (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873–884. https://doi.org/10.1056/NEJMoa061355 CrossRefPubMed

36.

Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT (2010) Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 28(18):2952–2957. https://doi.org/10.1200/JCO.2009.26.0695 CrossRefPubMed

37.

Burr NE, Talboys RJ, Savva S, Clark A, Phillips M, Metcalfe M, Dennison A, Robinson R, Lewis MP, Rhodes M, Rushbrook S, Hart AR (2014) Aspirin may prevent cholangiocarcinoma: a case-control study from the United kingdom. Dig Dis Sci 59(7):1567–1572. https://doi.org/10.1007/s10620-014-3056-z CrossRefPubMed

Title: Malignancy risk in Korean male patients with ankylosing spondylitis
Authors: Bora Nam
Hyoungyoung Kim
Eun Jin Jang
Soo-Kyung Cho
Yoon-Kyoung Sung
Tae-Hwan Kim
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Ankylosing Spondylitis
Pancreatic Cancer
Pancreatic Cancer
Published in: Rheumatology International / Issue 10/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-019-04408-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Malignancy risk in Korean male patients with ankylosing spondylitis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2019

Gait as predictor of physical function in axial spondyloarthritis: the prospective longitudinal FOLOMI (Function, Locomotion, Measurement, Inflammation) study protocol

Spontaneous coronary artery dissection in systemic lupus erythematosus: case-based review

Clinical manifestations and outcomes of musculoskeletal nontuberculous mycobacterial infections

Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study

Stiffening of aorta is more preferentially associated with rheumatoid arthritis than peripheral arteries

Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page